Figure 2. Progression-Free and Overall Survival.

Eligible patients with follow-up as of March 7, 2016. There were 29 events in a median of 17.5 months for progression-free survival (A) and 20 events in a median of 25.8 months in overall survival (B). Events were defined as unequivocal progression of disease, progressive disease as defined by RECIST 1.1, progressive disease defined by the Prostate Cancer Working Group bone scan progression criteria, or death due to disease.